Comparative Pharmacology
Head-to-head clinical analysis: IFEX versus MUSTARGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFEX versus MUSTARGEN.
IFEX vs MUSTARGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IFEX (ifosfamide) is an alkylating agent that crosslinks DNA strands, inhibiting DNA synthesis and transcription. It requires hepatic activation via CYP3A4 to form active metabolites (ifosfamide mustard and acrolein).
MUSTARGEN (mechlorethamine HCl) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
1.2 g/m2 intravenously daily for 5 consecutive days every 3 weeks, or 5 g/m2 as a 24-hour continuous infusion every 3 weeks.
IV: 0.4 mg/kg or 12 mg/m² BSA as a single dose or divided into 0.1 mg/kg/day for 4 days.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours in adults with normal renal function; prolonged in renal impairment.
Terminal half-life: 30-60 minutes (rapidly inactivated); clinical context: very short due to rapid hydrolysis and alkylation, necessitating rapid administration after reconstitution.
Renal: approximately 50-70% of the administered dose is excreted in urine as unchanged drug; biliary/fecal excretion is minimal, accounting for less than 5%.
Renal: 50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: minimal.
Category C
Category C
Alkylating Agent
Alkylating Agent